Solmaz Sahebjam

6.0k total citations · 2 hit papers
111 papers, 3.6k citations indexed

About

Solmaz Sahebjam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Solmaz Sahebjam has authored 111 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 51 papers in Genetics. Recurrent topics in Solmaz Sahebjam's work include Glioma Diagnosis and Treatment (48 papers), Brain Metastases and Treatment (47 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Solmaz Sahebjam is often cited by papers focused on Glioma Diagnosis and Treatment (48 papers), Brain Metastases and Treatment (47 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Solmaz Sahebjam collaborates with scholars based in United States, Canada and Italy. Solmaz Sahebjam's co-authors include Michael Lim, David A. Reardon, John H. Sampson, Antonio Omuro, Joachim M. Baehring, Ricardo Zwirtes, John S. Mort, Rama Khokha, Michael Carleton and Alba A. Brandes and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and SHILAP Revista de lepidopterología.

In The Last Decade

Solmaz Sahebjam

99 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2020 946 citations Michael Lim, Solmaz Sahebjam et al. profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Michael Lim, Solmaz Sahebjam et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Solmaz Sahebjam United States	28	1.7k	1.7k	1.1k	786	731	111	3.6k
Juan Manuel Sepúlveda-Sánchez Spain	29	1.7k 1.0×	1.5k 0.9×	723 0.7×	844 1.1×	1.2k 1.7×	181	3.9k
Jason T. Huse United States	22	1.6k 1.0×	1.1k 0.7×	978 0.9×	608 0.8×	1.1k 1.5×	49	3.5k
Oliver Bähr Germany	29	1.6k 1.0×	875 0.5×	528 0.5×	570 0.7×	1.0k 1.4×	65	3.3k
Yu Yao China	33	1.1k 0.7×	893 0.5×	563 0.5×	670 0.9×	1.1k 1.5×	112	3.0k
John Glod United States	25	1.1k 0.7×	1.3k 0.8×	464 0.4×	418 0.5×	1.4k 1.9×	86	3.3k
Brett L. Carlson United States	29	1.4k 0.9×	1.3k 0.8×	563 0.5×	271 0.3×	1.9k 2.6×	69	3.6k
Adrienne Boire United States	23	904 0.5×	1.4k 0.8×	1.3k 1.2×	593 0.8×	1.3k 1.7×	76	3.7k
Joon H. Uhm United States	37	2.1k 1.2×	907 0.5×	764 0.7×	380 0.5×	1.7k 2.3×	127	4.4k
Morris D. Groves United States	42	2.5k 1.5×	2.1k 1.3×	2.1k 2.0×	316 0.4×	1.4k 1.9×	109	4.9k
Marica Eoli Italy	30	2.0k 1.2×	693 0.4×	636 0.6×	460 0.6×	1.0k 1.4×	152	3.8k

Countries citing papers authored by Solmaz Sahebjam

Since Specialization

Citations

This map shows the geographic impact of Solmaz Sahebjam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solmaz Sahebjam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solmaz Sahebjam more than expected).

Fields of papers citing papers by Solmaz Sahebjam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solmaz Sahebjam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solmaz Sahebjam. The network helps show where Solmaz Sahebjam may publish in the future.

Co-authorship network of co-authors of Solmaz Sahebjam

This figure shows the co-authorship network connecting the top 25 collaborators of Solmaz Sahebjam. A scholar is included among the top collaborators of Solmaz Sahebjam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solmaz Sahebjam. Solmaz Sahebjam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Olivier Rixe, Capucine Baldini, et al.. (2025). First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer. 131(13). e35939–e35939. 2 indexed citations

Piña, Yolanda, Vincent Law, Solmaz Sahebjam, et al.. (2025). Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses. Neuro-Oncology. 27(12). 3237–3249.

Marrone, Kristen A., Joseph C. Murray, Josephine Feliciano, et al.. (2025). Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases. Journal of Neuro-Oncology. 175(2). 561–569.

Sahebjam, Solmaz, et al.. (2024). A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma. CPT Pharmacometrics & Systems Pharmacology. 14(3). 495–509. 1 indexed citations

Lin, Nancy U., Priya Kumthekar, Solmaz Sahebjam, et al.. (2023). Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. npj Breast Cancer. 9(1). 94–94. 9 indexed citations

Naing, Aung, John D. Powderly, John Nemunaitis, et al.. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for ImmunoTherapy of Cancer. 10(3). e004223–e004223. 12 indexed citations

Sahebjam, Solmaz, Nam Tran, Rachid Baz, et al.. (2022). Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma. OncoTargets and Therapy. Volume 15. 953–962. 4 indexed citations

Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations

Lin, Nancy U., Mark D. Pegram, Solmaz Sahebjam, et al.. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology. 39(24). 2667–2675. 67 indexed citations

10.

Reblin, Maija, Dana Ketcher, Steven K. Sutton, et al.. (2021). A randomized wait-list controlled trial of a social support intervention for caregivers of patients with primary malignant brain tumor. BMC Health Services Research. 21(1). 360–360. 11 indexed citations

11.

Mills, Matthew N., Yuki Kawahara, Nicholas Figura, et al.. (2021). The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Research and Treatment. 191(1). 209–217. 8 indexed citations

12.

Zamarin, Dmitriy, Omid Hamid, Asha Nayak-Kapoor, et al.. (2020). Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 26(17). 4531–4541. 52 indexed citations

13.

Tolaney, Sara M., Solmaz Sahebjam, Émilie Le Rhun, et al.. (2020). A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 26(20). 5310–5319. 144 indexed citations

14.

Piha‐Paul, Sarina A., Tara C. Mitchell, Solmaz Sahebjam, et al.. (2020). 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial. Regular and Young Investigator Award Abstracts. A255–A255. 3 indexed citations

15.

Reblin, Maija, Solmaz Sahebjam, Noah C. Peeri, et al.. (2019). Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida. Journal of Palliative Medicine. 22(10). 1202–1207. 26 indexed citations

16.

Sahebjam, Solmaz, Andrew B. Sharabi, Michael Lim, Pravin Kesarwani, & Prakash Chinnaiyan. (2017). Immunotherapy and radiation in glioblastoma. Journal of Neuro-Oncology. 134(3). 531–539. 28 indexed citations

17.

Ahmed, Kamran A., Y.A. Abuodeh, Michelle Echevarria, et al.. (2016). Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Annals of Oncology. 27(12). 2288–2294. 107 indexed citations

18.

Sahebjam, Solmaz, et al.. (2005). Lack of Tissue Inhibitor of Metalloproteinases-3 Results in an Enhanced Inflammatory Response in Antigen-Induced Arthritis. American Journal Of Pathology. 166(6). 1733–1740. 56 indexed citations

19.

Daneshi, Ahmad, et al.. (2004). Pulsatile tinnitus and carotid artery atherosclerosis.. PubMed. 10(2). 161–4. 15 indexed citations

20.

Najmabadi, Hossein, Roxana Kariminejad, Solmaz Sahebjam, et al.. (2001). THE β-THALASSEMIA MUTATION SPECTRUM IN THE IRANIAN POPULATION. Hemoglobin. 25(3). 285–296. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact